In a recent note issued to investors on Friday, equities researchers at HC Wainwright reiterated their “buy” rating for Puma Biotechnology (NASDAQ:PBYI). This endorsement comes with a price objective of $8.00 on the biopharmaceutical company’s stock, implying a noteworthy upside potential of 97.04% from its current trading price.
https://beststocks.com/puma-biotechnology-receives-buy-rating-and-shows-p/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.